Prevalence and patterns of the concurrent use of anticholinergics for the motor symptoms of Parkinson’s disease and acetylcholinesterase inhibitors in Parkinson’s disease patients with dementia: a cross-sectional study using Korea National Health Insurance claims data

Table 3 Distribution of Parkinson’s disease patients with dementia prescribed anticholinergics used to treat the motor symptoms of Parkinson’s disease and acetylcholinesterase inhibitors (ACHEIs) concurrently^a by the same or different healthcare organizations

Prescribed within the same or different healthcare organizations	No. of patients who used agents concurrently ^b (%)
Prescribed within the same organization	709 (83.71)
Prescribed by the same or different prescribers
Same prescriber	676 (95.35)
Different prescribers	81 (11.42)
Types of healthcare organizations
General hospitals	285 (33.65)
Clinics	168 (19.83)
Hospitals	145 (17.12)
Tertiary-care hospitals	106 (12.51)
Long-term care hospitals	61 (7.20)
Others ^c	6 (0.71)
Prescribed in different organizations	217 (25.62)

n = 847 Parkinson’s disease patients with dementia (concurrent use group)
Abbreviations: ACHEI Acetylcholinesterase inhibitor
^a Patients with concurrent use refer to patients prescribed both anticholinergics for the motor symptoms of Parkinson’s disease and ACHEIs for at least 2 months
^b Patients can be classified into more than one group. Thus, the sum of the proportion is greater than 100%
^c Type of healthcare organizations of which the proportion is < 1% are classified as “Others.”

ISSN: 1471-2318